Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

Semaglutide sells for $997 a month when branded under Ozempic and $1,349 a month for Wegovy. The haircut to Ozempic may have a spillover effect on competitor drugs from Eli Lilly — Mounjaro and ...

Raising the dose of Novo Nordisk A/S’s obesity drug Wegovy helped patients shed more pounds in a trial while still falling ...

and effective" semaglutide products, adding: "These drugs are inherently complex to compound safely, and the risks they pose to patient safety far outweigh any benefits." The Alliance for Pharmacy ...